STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry into a Material Definitive Agreement.
| 10.1 |
Securities Purchase Agreement dated as of March 30, 2018 between the Company and Accelmed |
| 10.2 |
Securities Purchase Agreement dated as of March 30, 2018 between the Company and Broadfin |
| 10.3 |
Securities Purchase Agreement dated as of March 30, 2018 between the Company and Sabby |
| 10.4 |
Form of Registration Rights Agreement |
| 10.5 |
Form of Leak-Out Agreement |
| 10.6 |
Form of Voting Undertaking |
| 10.7 |
Form of Subscription Agreement |
| 10.8 |
Employment Agreement dated March 30, 2018 between the Company and Dr. Dolev Rafaeli |
99.1Press Release dated April 2, 2018
STRATA Skin Sciences, Inc. ExhibitEX-10.1 2 ex_10-1.htm ACCELMED STOCK PURCHASE AGREEMENT DATED 3-30 -18 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN STRATA SKIN SCIENCES,…To view the full exhibit click
About STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN)
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.
hereAbout STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN)
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.